PLA2R1 and membranous glomerulonephritis: In view of the occurrence of early recurrences despite the decline in circulating antibody levels after transplantation, we suggest monitoring the anti-PLA2R1 antibody levels of patients with membranous nephropathy on the waiting list and discussing appropriate management according to each patient’s comorbidities and risk factors prior to transplantation.